{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:46:13Z","timestamp":1793767573393,"version":"4.6.1"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:p>\n                    Imlifidase, derived from a\n                    <jats:italic toggle=\"yes\">Streptococcus pyogenes<\/jats:italic>\n                    enzyme, cleaves the entire immunoglobulin G pool within hours after administration in fully cleaved antigen-binding and crystallizable fragments. These cleaved fragments can no longer exert their antibody-dependent cytotoxic functions, thereby creating a window to permit HLA-incompatible kidney transplantation. Imlifidase is labeled, in Europe only, for deceased donor kidney transplantation in highly sensitized patients, whose chances for an HLA-compatible transplant are negligible. This review discusses outcomes of preclinical and clinical studies on imlifidase and describes the phase III desensitization trials that are currently enrolling patients. A comparison is made with other desensitization methods. The review discusses the immunological work-up of imlifidase candidates and especially the \u201cdelisting strategy\u201d of antigens that shift from unacceptable to acceptable with imlifidase desensitization. Other considerations for clinical implementation, such as adaptation of induction protocols, are also discussed. Imlifidase cleaves most of the currently used induction agents except for horse antithymocyte globulin, and rebound of donor-specific antibodies should be managed. Another consideration is the timing and interpretation of (virtual) crossmatches when bringing this novel desensitization agent into the clinic.\n                  <\/jats:p>","DOI":"10.1097\/tp.0000000000004689","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:40:38Z","timestamp":1687308038000},"page":"335-345","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["Imlifidase Desensitization in HLA-incompatible Kidney Transplantation: Finding the Sweet Spot"],"prefix":"10.1097","volume":"108","author":[{"given":"Annelies E.","family":"de Weerd","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Erasmus Medical Center Transplant Institute, University Medical Center, Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave L.","family":"Roelen","sequence":"additional","affiliation":[{"name":"Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"van de Wetering","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus Medical Center Transplant Institute, University Medical Center, Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel G.H.","family":"Betjes","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus Medical Center Transplant Institute, University Medical Center, Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan","family":"Heidt","sequence":"additional","affiliation":[{"name":"Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies E.J.","family":"Reinders","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus Medical Center Transplant Institute, University Medical Center, Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1128\/jb.100.1.354-357.1969","article-title":"Distribution and serological specificity of sialidase produced by various groups of streptococci.","volume":"100","author":"Hayano","year":"1969","journal-title":"J Bacteriol"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1093\/emboj\/20.12.3046","article-title":"EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG.","volume":"20","author":"Collin","year":"2001","journal-title":"EMBO J"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1128\/IAI.71.6.2983-2992.2003","article-title":"Extracellular enzymes with immunomodulating activities: variations on a theme in Streptococcus pyogenes.","volume":"71","author":"Collin","year":"2003","journal-title":"Infect Immun"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1128\/IAI.70.7.3944-3947.2002","article-title":"Cysteine protease activity and histamine release from the human mast cell line HMC-1 stimulated by recombinant streptococcal pyrogenic exotoxin B\/streptococcal cysteine protease.","volume":"70","author":"Watanabe","year":"2002","journal-title":"Infect Immun"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/emboj\/21.7.1607","article-title":"IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G.","volume":"21","author":"von Pawel-Rammingen","year":"2002","journal-title":"EMBO J"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"e1692","DOI":"10.1371\/journal.pone.0001692","article-title":"IdeS: a bacterial proteolytic enzyme with therapeutic potential.","volume":"3","author":"Johansson","year":"2008","journal-title":"PLoS One"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/381982","article-title":"Low antibody levels against cell wall-attached proteins of Streptococcus pyogenes predispose for severe invasive disease.","volume":"189","author":"Akesson","year":"2004","journal-title":"J Infect Dis"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"e0132011","DOI":"10.1371\/journal.pone.0132011","article-title":"Complete removal of extracellular IgG antibodies in a randomized dose-escalation phase I study with the bacterial enzyme IdeS\u2014a novel therapeutic opportunity.","volume":"10","author":"Winstedt","year":"2015","journal-title":"PLoS One"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"4645","DOI":"10.1182\/bloodadvances.2022007195","article-title":"Anchoring IgG-degrading enzymes to the surface of platelets selectively neutralizes antiplatelet antibodies.","volume":"6","author":"Lynch","year":"2022","journal-title":"Blood Adv"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1111\/ajt.14733","article-title":"Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients.","volume":"18","author":"Lorant","year":"2018","journal-title":"Am J Transplant"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ajt.2022.11.025","article-title":"First use of imlifidase desensitization in a highly sensitized lung transplant candidate: a case report.","volume":"23","author":"Roux","year":"2023","journal-title":"Am J Transplant"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1056\/NEJMoa1612567","article-title":"IgG endopeptidase in highly sensitized patients undergoing transplantation.","volume":"377","author":"Jordan","year":"2017","journal-title":"N Engl J Med"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1097\/TP.0000000000003496","article-title":"Imlifidase desensitization in crossmatch-positive, highly sensitized kidney transplant recipients: results of an international phase 2 trial (Highdes).","volume":"105","author":"Jordan","year":"2021","journal-title":"Transplantation"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/SLA.0000000000002924","article-title":"IdeS (Imlifidase): a novel agent that cleaves human IgG and permits successful kidney transplantation across high-strength donor-specific antibody.","volume":"268","author":"Lonze","year":"2018","journal-title":"Ann Surg"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjh.15706","article-title":"Administration of immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS) for persistent anti-ADAMTS13 antibodies in patients with thrombotic thrombocytopenic purpura in clinical remission.","volume":"186","author":"Stubbs","year":"2019","journal-title":"Br J Haematol"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.humimm.2016.10.009","article-title":"Kidney transplantation of highly sensitized recipients under the new kidney allocation system: a reflection from five different transplant centers across the United States.","volume":"78","author":"Parsons","year":"2017","journal-title":"Hum Immunol"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1111\/ajt.17182","article-title":"Scandiatransplant acceptable mismatch program\u201410 years with an effective strategy for transplanting highly sensitized patients.","volume":"22","author":"Weinreich","year":"2022","journal-title":"Am J Transplant"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/1744666X.2018.1498335","article-title":"Transplantation in highly sensitized patients: challenges and recommendations.","volume":"14","author":"Heidt","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"e068769","DOI":"10.1136\/bmj-2021-068769","article-title":"Survival for waitlisted kidney failure patients receiving transplantation versus remaining on waiting list: systematic review and meta-analysis.","volume":"376","author":"Chaudhry","year":"2022","journal-title":"BMJ"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/ajt.16982","article-title":"OPTN\/SRTR 2020 annual data report: kidney.","volume":"22","author":"Lentine","year":"2022","journal-title":"Am J Transplant"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1097\/TP.0000000000004238","article-title":"Impact of sensitization on waiting time prior to kidney transplantation in Germany.","volume":"106","author":"Zecher","year":"2022","journal-title":"Transplantation"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"687254","DOI":"10.3389\/fimmu.2021.687254","article-title":"Highly sensitized patients are well served by receiving a compatible organ offer based on acceptable mismatches.","volume":"12","author":"Heidt","year":"2021","journal-title":"Front Immunol"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/ajt.15149","article-title":"The national landscape of deceased donor kidney transplantation for the highly sensitized: transplant rates, waitlist mortality, and posttransplant survival under KAS.","volume":"19","author":"Jackson","year":"2019","journal-title":"Am J Transplant"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1111\/j.1600-6143.2005.01024.x","article-title":"The Dutch national living donor kidney exchange program.","volume":"5","author":"de Klerk","year":"2005","journal-title":"Am J Transplant"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/TP.0000000000004262","article-title":"Seeking standardized definitions for HLA-incompatible kidney transplants: a systematic review.","volume":"107","author":"Jatana","year":"2023","journal-title":"Transplantation"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/ajt.12786","article-title":"Quantifying the risk of incompatible kidney transplantation: a multicenter study.","volume":"14","author":"Orandi","year":"2014","journal-title":"Am J Transplant"},{"key":"R29-20250604","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1056\/NEJMoa1508380","article-title":"Survival benefit with kidney transplants from HLA-incompatible live donors.","volume":"374","author":"Orandi","year":"2016","journal-title":"N Engl J Med"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.kint.2021.01.027","article-title":"Presence of a survival benefit of HLA-incompatible living donor kidney transplantation compared to waiting or HLA-compatible deceased donor kidney transplantation with a long waiting time.","volume":"100","author":"Koo","year":"2021","journal-title":"Kidney Int"},{"key":"R31-20250604","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(16)31595-1","article-title":"Post-listing survival for highly sensitised patients on the UK kidney transplant waiting list: a matched cohort analysis.","volume":"389","author":"Manook","year":"2017","journal-title":"Lancet"},{"key":"R32-20250604","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.ekir.2021.07.024","article-title":"Immortal time-bias-corrected survival of highly sensitized patients and HLA-desensitized kidney transplant recipients.","volume":"6","author":"Noble","year":"2021","journal-title":"Kidney Int Rep"},{"key":"R33-20250604","doi-asserted-by":"crossref","first-page":"10511","DOI":"10.3389\/ti.2022.10511","article-title":"European Guideline for the Management of Kidney Transplant Patients With HLA Antibodies: by the European Society for Organ Transplantation Working Group.","volume":"35","author":"Mamode","year":"2022","journal-title":"Transpl Int"},{"key":"R34-20250604","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/TP.0000000000004279","article-title":"Desensitization in crossmatch-positive kidney transplant candidates.","volume":"107","author":"Noble","year":"2023","journal-title":"Transplantation"},{"key":"R35-20250604","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1097\/TXD.0000000000001183","article-title":"HLA antibody incompatible renal transplantation: long-term outcomes similar to deceased donor transplantation.","volume":"7","author":"Krishnan","year":"2021","journal-title":"Transplant Direct"},{"key":"R36-20250604","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/TP.0000000000000064","article-title":"Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients.","volume":"98","author":"Vo","year":"2014","journal-title":"Transplantation"},{"key":"R37-20250604","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/ki.2014.261","article-title":"A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation.","volume":"87","author":"Jackson","year":"2015","journal-title":"Kidney Int"},{"key":"R38-20250604","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/TP.0000000000002909","article-title":"Donor-specific B cell memory in alloimmunized kidney transplant recipients: first clinical application of a novel method.","volume":"104","author":"Wehmeier","year":"2020","journal-title":"Transplantation"},{"key":"R39-20250604","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/ajt.13050","article-title":"Prospective iterative trial of proteasome inhibitor-based desensitization.","volume":"15","author":"Woodle","year":"2015","journal-title":"Am J Transplant"},{"key":"R40-20250604","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/TP.0000000000001330","article-title":"32 doses of bortezomib for desensitization is not well tolerated and is associated with only modest reductions in anti-HLA antibody.","volume":"101","author":"Moreno Gonzales","year":"2017","journal-title":"Transplantation"},{"key":"R41-20250604","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1097\/TXD.0000000000001139","article-title":"Marginal impact of tocilizumab monotherapy on anti-HLA alloantibodies in highly sensitized kidney transplant candidates.","volume":"7","author":"Daligault","year":"2021","journal-title":"Transplant Direct"},{"key":"R42-20250604","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/ajt.16926","article-title":"Clazakizumab for desensitization in highly sensitized patients awaiting transplantation.","volume":"22","author":"Vo","year":"2022","journal-title":"Am J Transplant"},{"key":"R43-20250604","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1111\/ajt.15364","article-title":"Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial.","volume":"19","author":"Marks","year":"2019","journal-title":"Am J Transplant"},{"key":"R44-20250604","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","article-title":"Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.","volume":"11","author":"Stegall","year":"2011","journal-title":"Am J Transplant"},{"key":"R45-20250604","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1681\/ASN.2017050589","article-title":"Complement-activating anti-HLA antibodies in kidney transplantation: allograft gene expression profiling and response to treatment.","volume":"29","author":"Lefaucheur","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"R46-20250604","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1111\/ajt.16754","article-title":"Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients.","volume":"21","author":"Kjellman","year":"2021","journal-title":"Am J Transplant"},{"key":"R47-20250604","doi-asserted-by":"crossref","first-page":"10128","DOI":"10.3389\/ti.2022.10128","article-title":"Dynamic behaviour of donor specific antibodies in the early period following HLA incompatible kidney transplantation.","volume":"35","author":"Phillpott","year":"2022","journal-title":"Transpl Int"},{"key":"R48-20250604","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-6143.2005.01178.x","article-title":"A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody.","volume":"6","author":"Stegall","year":"2006","journal-title":"Am J Transplant"},{"issue":"Suppl 1","key":"R49-20250604","first-page":"201","article-title":"Efficacy of immunoadsorption to reduce donor-specific alloantibodies in kidney-transplant candidates.","volume":"13","author":"Rostaing","year":"2015","journal-title":"Exp Clin Transplant"},{"key":"R50-20250604","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/ajt.15175","article-title":"Long-term outcomes of eculizumab-treated positive crossmatch recipients: allograft survival, histologic findings, and natural history of the donor-specific antibodies.","volume":"19","author":"Schinstock","year":"2019","journal-title":"Am J Transplant"},{"key":"R51-20250604","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.4049\/jimmunol.1501929","article-title":"The bacterial enzyme IdeS cleaves the IgG-type of B cell receptor (BCR), abolishes BCR-mediated cell signaling, and inhibits memory B cell activation.","volume":"195","author":"Jarnum","year":"2015","journal-title":"J Immunol"},{"key":"R52-20250604","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/TP.0000000000002516","article-title":"An easy and sensitive method to profile the antibody specificities of HLA-specific memory B cells.","volume":"103","author":"Karahan","year":"2019","journal-title":"Transplantation"},{"key":"R53-20250604","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/ajt.16363","article-title":"Estimating alloantibody levels in highly sensitized renal allograft candidates: using serial dilutions to demonstrate a treatment effect in clinical trials.","volume":"21","author":"Tambur","year":"2021","journal-title":"Am J Transplant"},{"key":"R54-20250604","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1432-2277.2004.tb00379.x","article-title":"HLAMatchmaker-based strategy to identify acceptable HLA class I mismatches for highly sensitized kidney transplant candidates.","volume":"17","author":"Duquesnoy","year":"2004","journal-title":"Transpl Int"},{"key":"R56-20250604","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1111\/ajt.15922","article-title":"Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab.","volume":"20","author":"Jordan","year":"2020","journal-title":"Am J Transplant"},{"key":"R57-20250604","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1097\/TP.0000000000004031","article-title":"Imlifidase-generated single-cleaved IgG: implications for transplantation.","volume":"106","author":"Bockermann","year":"2022","journal-title":"Transplantation"},{"key":"R58-20250604","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/ajt.16828","article-title":"Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation.","volume":"22","author":"Huang","year":"2022","journal-title":"Am J Transplant"},{"key":"R59-20250604","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1097\/TP.0000000000004329","article-title":"RE: imlifidase-generated single-cleaved IgG: implications for transplantation.","volume":"107","author":"de Weerd","year":"2023","journal-title":"Transplantation"},{"key":"R60-20250604","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/ajt.15067","article-title":"Dual targeting: combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients.","volume":"19","author":"Burghuber","year":"2019","journal-title":"Am J Transplant"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004689","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T14:14:14Z","timestamp":1749046454000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004689","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,19]]}}}